Drug Nanocarriers to Treat Autoimmunity and Chronic Inflammatory Diseases

Overview

Journal Semin Immunol

Specialty Allergy & Immunology

Date 2017 Sep 1

PMID 28855088

Citations 28

Authors

Davide Prosperi

Miriam Colombo

Ivan Zanoni

Francesca Granucci

Affiliations

Soon will be listed here.

Abstract

Nanoparticles represent a new generation of drug delivery systems that can be engineered to harness optimal target selectivity for specific cells and tissues and high drug loading capacity, allowing for improved pharmacokinetics and enhanced bioavailability of therapeutics. The spontaneous propensity of both organic and colloidal nanoparticles to be captured by the cells of the reticuloendothelial system encouraged their utilization as passive targeting systems that can be preferentially directed to innate immune cells, such as macrophages, dendritic cells and neutrophils. The natural affinity for phagocytic cells suggests the possible implementation of nanoparticles as an immunotherapeutic platform for inflammatory diseases and autoimmune disorders. Here we discuss the recent advances in the application of nanotechnology to induce antigen-specific tolerance in autoimmunity and the use of nanoparticles for anti-inflammatory therapies, including treatment of inflammatory bowel diseases, psoriasis and rheumatoid arthritis.

Citing Articles

Niosome Preparation Techniques and Structure-An Illustrated Review.

Mawazi S, Ge Y, Widodo R Pharmaceutics. 2025; 17(1).

PMID: 39861715 PMC: 11768252. DOI: 10.3390/pharmaceutics17010067.

Latest developments in biomaterial interfaces and drug delivery: challenges, innovations, and future outlook.

Patel S, Salaman S, Kapoor D, Yadav R, Sharma S Z Naturforsch C J Biosci. 2024; .

PMID: 39566511 DOI: 10.1515/znc-2024-0208.

Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis.

Liu C, Gong Q, Liu W, Zhao Y, Yan X, Yang T J Transl Med. 2024; 22(1):963.

PMID: 39448992 PMC: 11515557. DOI: 10.1186/s12967-024-05682-x.

Bone scaffolds-based localized drugs delivery for osteosarcoma: current status and future perspective.

Liang W, Long H, Zhang H, Bai J, Jiang B, Wang J Drug Deliv. 2024; 31(1):2391001.

PMID: 39239763 PMC: 11382735. DOI: 10.1080/10717544.2024.2391001.

Poly(malic acid)-budesonide nanoconjugates embedded in microparticles for lung administration.

Tessier B, Moine L, Peramo A, Tsapis N, Fattal E Drug Deliv Transl Res. 2024; 14(8):2062-2078.

PMID: 38517568 DOI: 10.1007/s13346-024-01571-4.

References

Bhavsar M, Tiwari S, Amiji M . Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release. 2005; 110(2):422-430. DOI: 10.1016/j.jconrel.2005.11.001. View

Metselaar J, Wauben M, Wagenaar-Hilbers J, Boerman O, Storm G . Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 2003; 48(7):2059-66. DOI: 10.1002/art.11140. View

Thao L, Byeon H, Lee C, Lee S, Lee E, Choi H . Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int J Pharm. 2015; 497(1-2):268-76. DOI: 10.1016/j.ijpharm.2015.12.004. View

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

Bhavsar M, Amiji M . Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release. 2007; 119(3):339-48. DOI: 10.1016/j.jconrel.2007.03.006. View

Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L . 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 2007; 123(3):211-8. DOI: 10.1016/j.jconrel.2007.08.008. View

Ferrari M . Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5(3):161-71. DOI: 10.1038/nrc1566. View

Lewis J, Zaveri T, Crooks 2nd C, Keselowsky B . Microparticle surface modifications targeting dendritic cells for non-activating applications. Biomaterials. 2012; 33(29):7221-32. PMC: 3428206. DOI: 10.1016/j.biomaterials.2012.06.049. View

Xia Y . Editorial: are we entering the nano era?. Angew Chem Int Ed Engl. 2014; 53(46):12268-71. DOI: 10.1002/anie.201406740. View

10.

Thomas T, Goonewardena S, Majoros I, Kotlyar A, Cao Z, Leroueil P . Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 2011; 63(9):2671-80. PMC: 3168725. DOI: 10.1002/art.30459. View

11.

Moulari B, Pertuit D, Pellequer Y, Lamprecht A . The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008; 29(34):4554-60. DOI: 10.1016/j.biomaterials.2008.08.009. View

12.

Eifler A, Thaxton C . Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol. 2011; 726:325-38. DOI: 10.1007/978-1-61779-052-2_21. View

13.

Lautenschlager C, Schmidt C, Lehr C, Fischer D, Stallmach A . PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm. 2013; 85(3 Pt A):578-86. DOI: 10.1016/j.ejpb.2013.09.016. View

14.

Lakshmi P, Devi G, Bhaskaran S, Sacchidanand S . Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol. 2007; 73(3):157-61. DOI: 10.4103/0378-6323.32709. View

15.

Brunner T, Cohen S, Monsonego A . Silencing of proinflammatory genes targeted to peritoneal-residing macrophages using siRNA encapsulated in biodegradable microspheres. Biomaterials. 2009; 31(9):2627-36. DOI: 10.1016/j.biomaterials.2009.12.011. View

16.

Metcalfe S, Fahmy T . Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol Med. 2011; 18(2):72-80. DOI: 10.1016/j.molmed.2011.11.002. View

17.

Cevc G, Blume G . Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta. 2004; 1663(1-2):61-73. DOI: 10.1016/j.bbamem.2004.01.006. View

18.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View

19.

Golden J, McCormick T, Ward N . IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013; 62(2):195-201. PMC: 3640599. DOI: 10.1016/j.cyto.2013.03.013. View

20.

Moon J, Huang B, Irvine D . Engineering nano- and microparticles to tune immunity. Adv Mater. 2012; 24(28):3724-46. PMC: 3786137. DOI: 10.1002/adma.201200446. View